Alnylam Updates Phase 3 TRITON-CM Study for Nucresiran
Alnylam Pharmaceuticals announced an update to its Phase 3 TRITON-CM study of nucresiran, expanding the target enrollment to approximately 2,250 patients.
Stocks · News reference
Alnylam Pharmaceuticals Reports Q3 2026 Financial Results
Alnylam Pharmaceuticals announced its third-quarter 2026 financial results, reporting revenue of $1.46 billion and adjusted EPS of $16.26, while reaffirming its full-year 2026 financial outlook.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Filed: 2026-10-29 AccNo: 0001178670-26-000074 Size: 513 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Alnylam Announces Positive Initial Phase 1b Data for Brezosiran in Huntington's Disease
Alnylam Pharmaceuticals reported positive initial Phase 1b clinical trial results for brezosiran (ALN-HTT02), demonstrating deep and durable reductions of mutant huntingtin protein in patients with Huntington's disease.